Cost-effectiveness and resource use analysis of patients with asthma before and after treatment with mepolizumab in a real-life setting

Abstract

Objective

To define the cost-effectiveness and health resource use of mepolizumab in a cohort of patients with severe eosinophilic asthma in real-life conditions in Spain.

Methods

This was an observational, retrospective, single-center study. Patients included were diagnosed with severe eosinophilic asthma and treated with mepolizumab 100 mg subcutaneous (SC) 4-weekly for 12 months. Outcomes evaluated: incremental cost-effectiveness ratio (ICER), number of exacerbations, disease control with the Asthma Control Test (ACT), Asthma Quality of Life Questionnaire (AQLQ), and direct and indirect cost per patient.

Results

12 months after mepolizumab initiation, a significant decrease in exacerbations was shown, from a mean (standard deviation [SD]) of 3.1 (2.6) to 0.7 (1.5), an increase from 4.9 (0.4) to 6.1 (0.5) in AQLQ, and from 14.9 (5.7) to 21.5 (3.9) in ACT scores. The number of cortico-dependent patients significantly decreased from 53.3% to 13.3% during this period. There was a significant decrease of 94% in the cost of hospitalization, from a mean (SD) of €4063.9 (5423.9) pretreatment to €238.6 (1306.9) post-treatment (p = 0.0003). Total costs decreased significantly from a median of €2,423.1 (1,512.8; 9,320.9) pretreatment to €1,177.5 (965.0; 1,737.8) post-treatment if mepolizumab was excluded. ICER per exacerbation avoided was €3606.9, per 3-point ACT score increase €3934.8, and per 0.5-point AQLQ score increase €3606.9.

Conclusions

Mepolizumab improves control of asthma and quality of life in patients with severe diseases in a cost-effectiveness range. The number of exacerbations decreased, and there was a clear reduction in primary care visits and hospitalizations. Further economic analyses of biological therapies for asthma are required.

Keywords:

• Treatment
• management/control
• economics

Acknowledgements

It is appreciated to IQVIA España for his participation and help in data analysis of the study.

Disclosure statement

JDO has received funding for research, honoraria for consultancy and conferences from AstraZeneca, Chiesi y GSK; honoraria for consultancy and conferences from Bial, Novartis, Sanofi and Teva; and speaker fees from ALK, LETI Pharma and Mundipharma. DBC is employee of GSK and holds stocks/shares in GSK. FVS declares no conflict of interest for this work. DL declares no conflict of interest for this work. SQ has been on advisory boards for and has received speaker’s honoraria from ALK, Allergy Therapeutics, AstraZeneca, GlaxoSmithKline, Leti, Novartis, Chiesi, Mundipharma, Teva and Sanofi.

Data availability statement

The study has been done based on anonymized medical charts of the Hospital de la Paz (Madrid) patients.

Additional information

Funding

This work was supported by GlaxoSmithKline España and it is appreciated to IQVIA España for his participation and help in data analysis of the study.